Literature DB >> 10022319

Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein.

P Chomarat1, J M Rice, B L Slagle, C P Wild.   

Abstract

Hepatitis B virus (HBV) and aflatoxins are major risk factors for hepatocellular carcinoma (HCC) exhibiting a synergistic interaction in the development of this disease. The molecular mechanisms of this interaction remain to be elucidated but an altered carcinogen metabolism in the presence of hepatitis-induced liver injury is one hypothesis. The availability of biomarkers of aflatoxin exposure and metabolism permits this hypothesis to be examined in human populations whilst animal models, such as HBV transgenic mice permit parallel studies in an experimental setting. The hepatitis B virus X protein (HBx) is suspected to play a role in the hepatocarcinogenic process by virtue of its capacity to transactivate oncogenes and several other cellular genes via cis-acting elements. In previous studies in HBV transgenic mice expressing the HB surface antigen and X genes we observed a marked induction of specific cytochrome P450s (CYP) (Kirby et al., 1994a). In the current study we investigated the status of CYP, glutathione S-transferases (GST) and antioxidant enzymes in mice carrying only the X gene under the control of the alpha-1 antitrypsin regulatory elements (ATX mice). Livers of ATX mice showed no major pathological alterations compared to age-matched non-transgenic control mice. Immunohistochemical staining for CYP1A, 2A5 and GST expression and determination of related enzymatic activities (7-ethoxyresorufin O-deethylation, 7-methoxyresorufin O-deethylation, coumarin 7-hydroxylation and GST activities) revealed no differences between control and ATX mice. In addition, no differences in antioxidant enzymes were observed. Overall, these results support the conclusion that HBx expression alone is insufficient to induce transactivation of CYP and GST genes or to alter the antioxidant system and that the induction in other HBV models is a result of inflammatory injury in the liver, a feature absent in ATX mice. These data are compared to biomarker studies of enzyme activities in aflatoxin-exposed human populations with and without HBV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10022319     DOI: 10.1016/s0378-4274(98)00254-9

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

1.  Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions.

Authors:  C R Madden; M J Finegold; B L Slagle
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B.

Authors:  Ke-Xia Wang; Jiang-Long Peng; Xue-Feng Wang; Ye Tian; Jian Wang; Chao-Pin Li
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

3.  Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment.

Authors:  Chang-Zheng Ke; Yue Chen; Zuo-Jiong Gong; Zhong-Ji Meng; Li Liu; Ze-Jiu Ren; Zuo-Hua Zhou
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

4.  Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein.

Authors:  Charles R Madden; Milton J Finegold; Betty L Slagle
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumorigenesis in mice.

Authors:  Min Lian; Ying Liu; Shun-Zhang Yu; Geng-Sun Qian; Shu-Guang Wan; Kenneth-R Dixon
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

6.  Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Effects of Aflatoxin B1 and Hepatitis B Virus on Promoting Hepatocarcinogenesis.

Authors:  Yongdong Niu; Shaohua Fan; Qin Luo; Liming Chen; Danmei Huang; Wenjun Chang; Wenxin Qin; Ganggang Shi
Journal:  J Clin Transl Hepatol       Date:  2021-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.